Filed Pursuant to Rule 424(b)(2)
Registration No. 333-278934
PROSPECTUS SUPPLEMENT
(To Prospectus Dated May 31, 2024)

UBS AG
This prospectus supplement applies to market-making offers and sales of outstanding debt securities originally issued by Credit Suisse AG under the following registration statements (and solely with respect to such outstanding debt securities that are not specifically identified in any other document filed by UBS on the date of this prospectus supplement in connection with the Merger (as defined below)): 333-272539, 333-238458-02, 333-218604-02, 333-202913, 333-180300-03, 333-158199-10 (each a “CS Registration Statement” and collectively, the “CS Registration Statements”, and such outstanding debt securities collectively, the “debt securities”).
On December 7, 2023, UBS AG and Credit Suisse AG (“CS AG”) entered into a merger agreement (as such agreement was amended from time to time, the “Merger Agreement”). Pursuant to the terms of the Merger Agreement, UBS AG and CS AG agreed to a merger by absorption under Swiss law (Absorptionsfusion) whereby CS AG (including its branches) would be absorbed by UBS AG (the “Merger”), and effective upon registration of the Merger with the Commercial Registers of the Canton of Zurich and the Canton of Basel-City in Switzerland, CS AG would cease to exist and all of its assets, liabilities and contracts would automatically transfer to, and be absorbed and taken over by, UBS AG by operation of Swiss law (Universalsukzession). The Merger was completed on May 31, 2024 (the “Effective Date”).
In connection with the Merger, on May 30, 2024, UBS AG, CS AG and The Bank of New York Mellon (formerly known as The Bank of New York), as trustee (the “Trustee”), entered into a fourth supplemental indenture (the “Fourth Supplemental Indenture”) to the senior indenture between CS AG and the Trustee dated as of March 29, 2007 (as supplemented, the “Senior Indenture”). Pursuant to the Fourth Supplemental Indenture and effective upon completion of the Merger and by operation of Swiss law, UBS AG expressly assumed all of CS AG’s obligations, and succeeded to all of CS AG’s rights, under the Senior Indenture and all outstanding and future securities issued thereunder, including the debt securities. Consequently, upon completion of the Merger on the Effective Date, UBS AG became the issuer of the debt securities. After giving effect to the Merger, all other terms and conditions of the debt securities remained unchanged. Unless the context otherwise requires and except as otherwise indicated, in this prospectus supplement, the terms “we,” “us” and “our” refer to UBS AG on a parent only basis. “UBS” or the “Group” refers to UBS Group AG and its consolidated subsidiaries.
UBS AG has prepared the accompanying new “base” prospectus dated May 31, 2024 (the “base prospectus”), which replaces any prior base prospectuses with respect to the debt securities. UBS AG has also prepared a prospectus supplement to the base prospectus dated May 31, 2024 (together with the base prospectus, the “accompanying prospectus”). Because after giving effect to the Merger the terms of the debt securities remain otherwise unchanged, UBS AG is continuing to use the applicable original pricing supplements, product supplements and prospectus supplements for the debt securities (each, a “disclosure document”). As a result, you should read the disclosure documents relating to your debt securities, which give the specific terms of your debt securities, together with the accompanying prospectus. When you read the original disclosure documents, please note that any references to the applicable base prospectus dated prior to May 31, 2024, or to any sections of such base prospectus, should refer instead to the base prospectus, or to any corresponding section of the accompanying prospectus, and all references to CS AG as the issuer should be replaced with references to UBS AG as the issuer.
Neither the Securities and Exchange Commission (the “SEC”) nor any other regulatory body has approved or disapproved of the debt securities or passed upon the adequacy or accuracy of this prospectus supplement, the accompanying prospectus or any related pricing supplement or prospectus supplement. Any representation to the contrary is a criminal offense.
The debt securities are not deposit liabilities and are not insured by the Federal Deposit Insurance Corporation or any other governmental agency of the United States, Switzerland or any other jurisdiction. The debt securities will not have the benefit of any agency or governmental guarantee.
This prospectus supplement may be used by UBS Securities LLC, UBS Financial Services Inc., Credit Suisse Securities (USA) LLC or any other affiliate of UBS AG in connection with offers and sales of the debt securities in market-making transactions. In a market-making transaction, UBS Securities LLC, UBS Financial Services Inc., Credit Suisse Securities (USA) LLC or any other affiliate of UBS AG may resell the debt securities it acquires from other holders, after the original offering and sale of the debt security. Resales of this kind may occur in the open market or may be privately negotiated at prevailing market prices at the time of resale or at related or negotiated prices. In these transactions, UBS Securities LLC, UBS Financial Services Inc., Credit Suisse Securities (USA) LLC or any other affiliate of UBS AG may act as principal or agent, including as agent for the counterparty in a transaction in which it acts as principal, or as agent for both counterparties in a transaction in which it does not act as principal. UBS Securities LLC, UBS Financial Services Inc., Credit Suisse Securities (USA) LLC or any other affiliate of UBS AG may receive compensation in the form of discounts and commissions, including from both counterparties in some cases.
May 31, 2024.